Search results

Skip to results

Type

Status

Last updated

Showing 46 to 60 of 109 results for paclitaxel

  1. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.

  2. Bladder cancer: diagnosis and management (NG2)

    This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.

  3. Past appeals and decisions

    cancer - paclitaxel (review) 12 November 2002 TA389 Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride,...

  4. Past appeals and decisions

    cancer - paclitaxel (review) 12 November 2002 TA389 Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride,...

  5. Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)

    Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.

  6. Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

    Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer in adults.

  7. Advanced breast cancer: diagnosis and treatment (CG81)

    This guideline covers care and support for people with advanced (stage 4) breast cancer. It aims to help them and their healthcare professionals make shared decisions about tests and treatments to improve outcomes and quality of life.

  8. Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

    Evidence-based recommendations on Nivolumab (Opdivo) for previously treated unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma in adults.

  9. Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (TA779)

    Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.

  10. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

    Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults.

  11. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults.

  12. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

  13. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued [GID-TAG440]

  14. PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502

    Discontinued [GID-TA10402]

  15. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]